|Articles|February 1, 1998

Clinical and Economic Considerations in the Prevention of Osteoporosis Among Postmenopausal Women
Volume 4
Issue 2 Suppl

Potential Impact of Emerging Therapies on Osteoporosis Prevention

Author(s)Michael R. McClung, MD, Steven R. Goldstein, MD

Download PDF: Potential Impact of Emerging Therapies on Osteoporosis Prevention

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction: Approaches to Prevention of Postmenopausal Osteoporosis -- The Impact of Emerging Therapies

over 28 years ago

Article

Current Approaches to Osteoporosis Prevention

over 28 years ago

Article

Patient-Provider Decisions About Long-Term Therapy

over 28 years ago

Article

An Emerging Approach to Osteoporosis Prevention

over 28 years ago

Article

The Management of the Patient with Osteoporosis: A Modern Epidemic

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Potential Impact of Emerging Therapies on Osteoporosis Prevention

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Potential Impact of Emerging Therapies on Osteoporosis Prevention

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO